Early, but not late, treatment with human umbilical cord blood-derived mesenchymal stem cells attenuates cisplatin nephrotoxicity through immunomodulation
Home »
Publications » Early, but not late, treatment with human umbilical cord blood-derived mesenchymal stem cells attenuates cisplatin nephrotoxicity through immunomodulation
Publish Date 06/06/2024
Category
Keywords
Early, but not late, treatment with human umbilical cord blood-derived mesenchymal stem cells attenuates cisplatin nephrotoxicity through immunomodulation
Join the Arbor Assays Newsletter
Sign up for Arbor Assays’ email list to stay up to date on special deals, new kits, and published articles featuring Arbor Assays’ products
